BLUEBIRD BIO, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Eastern District of New York against bluebird bio, Inc.
All investors who purchased shares of bluebird bio, Inc. and incurred losses are urged to contact the firm immediately at classmember@whafh.com or (800) 575-0735 or (212) 545-4774. You may obtain additional information concerning the action or join the case on our website, www.whafh.com.
If you have incurred losses in the shares of bluebird bio, Inc., you may, no later than
CLICK HERE TO JOIN CASE
The filed complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, and failed to disclose to investors that:
- data supporting bluebird's BLA submission for LentiGlobin for SCD was insufficient to demonstrate drug product comparability;
- Defendants downplayed the foreseeable impact of disruptions related to the COVID-19 pandemic on the Company's BLA submission schedule for LentiGlobin for
SCD, particularly with respect to manufacturing; - because of all the foregoing, it was foreseeable that the Company would not submit the BLA for LentiGlobin for SCD in the second half of 2021; and
- as a result, the Company's public statements were materially false and misleading at all relevant times.
The price of Company shares dropped as much as 35% on
The company suspended the studies due to a reported Suspected Unexpected Serious Adverse Reaction (SUSAR) of acute myeloid leukemia (AML). Bluebird placed the study on hold after receiving a report last week that a patient who was treated more than five years ago in a study was diagnosed with AML.
If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact
Contact:
Email: gstone@whafh.com, kcooper@whafh.com or classmember@whafh.com
Tel: (800) 575-0735 or (212) 545-4774
View original content to download multimedia:http://www.prnewswire.com/news-releases/bluebird-bio-inc-class-action-alert-wolf-haldenstein-adler-freeman--herz-llp-announces-that-a-securities-class--action--lawsuit--has--been--filed--in--the--united-states-district-court-for-the-eastern-district-of-new-york-agai-301231506.html
SOURCE